Eli Lilly Stock Is Rising Tuesday: What's Going On?
Eli Lilly Stock Is Rising Tuesday: What's Going On?
The move is part of the Biden-Harris Administration's national strategy on Hunger, Nutrition and Health focused on ending hunger and reducing diet-related diseases such as obesity. Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid.
禮來（紐交所: LLY）股價週二有所上漲，此前拜登-賀錦麗政府提議一項新規定，擴大對擁有醫療保險和醫療補助的美國人提供抗肥胖藥物的覆蓋範圍。
What Happened: The government has proposed a new rule to expand access to medications for obesity. In a statement released Monday, the Biden-Harris Administration said Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95% for some enrollees. Approximately 4 million Medicaid enrollees would also gain access to these medications.
事件經過: 政府提議一項新規定，擴大肥胖藥物的使用範圍。拜登-賀錦麗政府週一發佈的一份聲明中表示，醫療保險將使這些處方藥對一些參保人員的自付費用降低至95%。大約400萬醫療補助參保人員也將獲得使用這些藥物的權限。
"The President is proud of the fact that the Inflation Reduction Act allows Medicare to negotiate down the price of drugs, a tool that will help Medicare lower the cost of some of the most expensive medications in the program. That power to negotiate drug prices is critical because Americans pay two to three times more than people in other countries for their prescription drugs," the White House said in a statement.
「總統爲《通脹削減法案》允許醫療保險就藥品價格進行議價感到自豪，這一工具將幫助醫療保險降低節目中一些最昂貴藥物的成本。議價藥品價格的能力至關重要，因爲美國人爲他們的處方藥付出的費用是其他國家人數的兩到三倍高。」 白宮在一份聲明中表示。
The move is part of the Biden-Harris Administration's national strategy on Hunger, Nutrition and Health focused on ending hunger and reducing diet-related diseases such as obesity.
此舉是拜登-賀錦麗政府關於結束飢餓、減少肥胖等與飲食有關疾病的國家戰略的一部分。
The anti-obesity drug market has expanded in recent years with FDA approval for a new class of drugs like Eli Lilly's Zepbound, which can cost close to $1,000 per month for those paying out-of-pocket.
最近幾年，隨着FDA批准了類似禮來的 Zepbound 這類新藥物，抗肥胖藥物市場有所擴大，對那些自費購買的人來說，這些藥物的成本可能接近每月1000美元。
One of the main parts of the Biden-Harris Administration's strategy involves recognizing the opportunity within Medicare and Medicaid to support access to nutritious foods, obesity counseling and other nutrition-related services.
拜登-賀錦麗政府戰略的主要部分之一是認識到在醫療保險和醫療補助中支持獲得營養食品、肥胖諮詢和其他營養相關服務的機會。
"Obesity is a multi-faceted disease and we need to work on all levels from prevention to treatment to address this persistent challenge," the White House said.
「肥胖是一個多方面的疾病，我們需要在預防、治療等各個層面上努力應對這一持續挑戰，」 白宮表示。
Eli Lilly's Zepbound generated $1.26 billion in sales for the company in its most recent quarter. Eli Lilly said Mounjaro and Zepbound sales in the third quarter were negatively impacted by inventory decreases in the wholesaler channel.
禮來的 Zepbound 在公司最近一個季度實現了12.6億美元的銷售額。禮來表示，Mounjaro 和 Zepbound 的銷售在第三季度受到批發商渠道庫存減少的影響。
LLY Price Action: Eli Lilly shares were up 3.58% at $782.00 at the time of publication Tuesday, according to Benzinga Pro.
禮來股價表現：根據Benzinga Pro的數據，在週二發佈時，禮來股價上漲了3.58%，報收782.00美元。
Photo: Shutterstock.
照片：shutterstock。
譯文內容由第三人軟體翻譯。
